Compare Bristol-Myers Squibb Co (BMY) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs DENTSPLY SIRONA Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.88 (market cap $130.12B), while DENTSPLY SIRONA Inc trades at $11.46 (market cap $2.27B). The key difference: Bristol-Myers Squibb Co is far larger — about 57.3× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| BMY | XRAY | |
|---|---|---|
Market Cap | $130.12B | $2.27B |
Sector | Health | Health |
52-Week High | $65.89 | $14.68 |
52-Week Low | $42.60 | $9.64 |
Enterprise Value | $164.11B | $4.35B |
Dividend Yield | 3.96% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
DENTSPLY SIRONA (XRAY) trades at $11.32, down 2.92% today, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $0.52, beating expectations, but revenue declined 4.1% year-over-year. Net income remains negative, though margins show improvement. The stock is near its consensus price target of $11.50, with support at $11 and resistance at $12.
Outlook is cautious; while cost controls and new partnerships offer potential, persistent revenue declines and high debt levels pose significant risks. Analyst sentiment is predominantly Hold, reflecting uncertainty around the turnaround plan's success amid weak dental market demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
